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Introduction
The HIV seroprevalence among adult medical inpatients 
at Queen Elizabeth Central Hospital (QECH) in Blantyre, 
Malawi is approximately 75%, and about one-third of  the 
patients with HIV are on antiretroviral therapy (ART).1 The 
proportion of  adult medical inpatients on ART increased 
from 25% in 2013 to 28% in 2014 and 31% in 2015 (Peterson 
I, QECH electronic patient record data, 2016, personal 
communication). Malawi HIV guidelines recommend 
targeted viral load (VL) testing for patients who have been 
on ART for at least one year, present with a WHO stage 3 
or 4 clinical event, and report good recent adherence to their 
ART regimen. A switch to a second-line ART regimen is only 
indicated after a VL result >5000 copies/mL confirms ART 
failure.2 QECH is a tertiary referral hospital and processes 
batched dried blood spot (DBS) VL samples in its central 
laboratory. Inpatients requiring VL testing during admission 
are instructed to attend the outpatient HIV clinic 3 to 4 
weeks later to obtain results. There are already significant 
challenges in linking HIV-infected patients to regular follow-
up and ART. As the Malawian ART programme continues 
to develop, there is a greater risk that patients established 
on ART will present with ART treatment failure and that 
the current VL testing systems may not be robust enough 
to meet service demands to facilitate a timely switch of  
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ART. We therefore prospectively studied targeted VL testing 
among adult inpatients at QECH and report outcomes at 8 
weeks post-discharge.
Methods
Ethical approval for this study was granted by the College 
of  Medicine Research and Ethics Committee (COMREC). 
Over a 4-week period, all adult medical admissions were 
screened for the following eligibility criteria: patients on 
ART for at least one year and presenting with a WHO 
stage 3 or 4 clinical event, with self-reported excellent ART 
adherence (taken ART as prescribed over the previous 
one month). Written consent was obtained from each 
patient. Demographic information, duration on ART, and 
self-reported ART adherence data were collected through 
patient interviews and review of  clinical files. Inpatient 
notes were reviewed daily to ascertain whether VL testing 
was ordered and carried out. At 3, 6, and 8 weeks following 
patient discharge, the laboratory VL database was checked 
for available results, which were triangulated with the HIV 
outpatient clinic electronic database to determine if  patients 
had attended the HIV clinic, received their results, and 
were switched to second-line treatment (if  indicated). Two 
attempts were made to contact patients via telephone, 8 
weeks post-discharge, to obtain information on health status.
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Abstract
Background
Approximately 75% of  medical inpatients at Queen Elizabeth Central Hospital (QECH) in Blantyre, Malawi are HIV seropositive, and a 
third of  these patients are on antiretroviral therapy (ART). Malawi guidelines recommend targeted viral load (VL) testing for patients on 
ART for at least one year who report excellent adherence and present with a WHO clinical stage 3 or 4 HIV disease. A switch to second-
line ART is only indicated if  a VL result >5000 copies/mL confirms treatment failure.
Methods
During an audit of  targeted VL testing at QECH, all adult medical admissions were screened to identify those in need of  VL testing. 
Daily review of  inpatient notes ascertained whether VL testing was ordered and carried out. At 8 weeks post-discharge the laboratory 
database was checked for results and was triangulated with the HIV outpatient database to ascertain whether patients had attended clinic, 
received results, and if  these results had been acted upon.
Results
Out of  81 patients recruited, 63 (77%) had a VL requested. At 8 weeks post-discharge, nine patients (14%) had VL results available. The 
median (IQR) waiting time for those with results was 29 days (20-47). Five patients had a VL >5000 copies/mL. Of  these patients, three 
attended clinic and one was switched to second-line ART. Of  the remaining 55 patients awaiting results, the median (IQR) waiting time 
at the 8-week follow-up point was 72 days (67-80). At 8 weeks post-discharge, 8 patients (33%) had died.
Conclusions
Our findings demonstrate challenges with targeted VL testing at QECH. Only two-thirds of  patients with clinical ART failure were 
identified as eligible for targeted VL testing, and of  these less than one-sixth had VL results available after 8 weeks. Interventions such as 
point-of-care targeted VL testing could result in faster turnaround times. In the interim, we suggest further evaluation of  the possibility 
of  switching patients with clinical ART failure and a low CD4 count to second-line ART while awaiting VL results.
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Results
Eighty-eight patients were screened and 85 patients consented 
to be enrolled in the study. Four patients were later excluded 
when their ultimate discharge diagnosis was no longer 
a WHO stage 3 or 4 condition. Data for 81 patients were 
included in the final analysis. The median (IQR) age was 37 
years (31-43), and the median (IQR) duration on ART was 
47 months (23-84). The median (IQR) CD4 count during 
the previous 6 months was 94.5 cells/uL (14.5-211). The 
most common clinical events were tuberculosis, community-
acquired pneumonia, bacterial meningitis, and non-typhoidal 
Salmonella sepsis. Table 1 summarises the frequency of  each 
clinical diagnosis in the study population during the data 
collection period.
Twenty-nine patients had at least two WHO stage 3 and 
4 conditions. Figure 1 demonstrates the pathway a patient 
needs to undergo in order to receive VL results. Figure 2 
summarises the VL testing pathway experienced by the study 
population. During admission, 63 patients (78%) had a VL 
requested by their clinician and, at 8 weeks after discharge, 
9 patients (14%) ultimately had a VL result available in the 
laboratory. The median (IQR) waiting time from blood 
sampling to available results was 29 days (20-47). Four 
of  the nine patients with results had an undetectable VL. 
The median (IQR) VL result of  the remaining 5 patients 
was 5.33log10 (4.57log10 to 5.46log10). Three of  the 
five patients with a high VL attended clinic and one was 
switched to a second-line ART regimen. Of  the remaining 
55 patients awaiting results, the median (IQR) waiting time 
from admission to 8-week follow-up was 72 days (67-80). 
The laboratory reported that during the study period there 
was a lack of  reagents and therefore a large backlog in VL 
test processing. Outcome data at the 8-week follow-up point 
were available for 24 of  the 68 patients discharged alive. Of  
these, 8 (33%) had died and 5 (21%) reported to be in poor 
health. Figure 3 summarises outcome data.
Discussion
Our findings demonstrate challenges with targeted VL 
testing at QECH. Even in this tertiary facility, only two-
thirds of  patients with clinical ART failure were identified 
by clinicians as eligible for targeted VL testing, and of  these 
less than one-sixth had VL results available 8 weeks after 
discharge. Those with available results had waited four weeks 
Table 1: Summary of  WHO stage 3 and 4 HIV diseases in the 
study population
WHO stage 3 or 4 condition Frequency
Tuberculosis 32
Community-acquired pneumonia 17
Non-typhoidal Salmonella sepsis 5
Bacterial meningitis 5
Disseminated Kaposi sarcoma 4
Cryptococcal meningitis 4
Oesophageal candidiasis 4
Sepsis (source unknown) 3
Other* 7
*Other: HIV encephalitis, HIV wasting syndrome, intracranial space occupying 
lesion (?lymphoma), lung abscess, E. coli sepsis, HIV-associated nephropathy, 
Pneumocystis jirovecii pneumonia
Clinician identifies 
patient for viral load 
testing
Patient or guardian 
collects request form 
from outpatient clinic
Patient visits 
laboratory for blood 
sample collection
Patient returns to 
laboratory after a 
minimum of 2 weeks 
to collect results (if 
available)
Patient attends 























Figure 2: Viral load (VL) testing pathway for study patients including median waiting time for viral load results
Figure 1: Intended viral load testing pathway at Queen Elizabeth Central Hospital
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on average. Ultimately, only one patient was switched to a 
second-line regimen. The mortality rate in those who could 
be contacted was high.
The VL testing pathways at QECH are complex, with 
many steps required before a patient can receive results, as 
demonstrated in Figure 1. Delays are experienced throughout 
this process. Many patients were identified as needing a VL 
test, but because they were too sick and did not have relatives 
or guardians to escort them from the inpatient wards to the 
laboratory, these patients did not attend the laboratory for 
blood sampling,. Blood sampling is not carried out on the 
wards because of  the need for dried blood spot testing and 
poor linkage of  patients to their results when samples are 
obtained during their ward stays.
This was a single-centre experience, but we believe that 
our findings are likely to be generalisable to inpatients at 
other hospitals in Malawi, particularly those where there is 
no onsite testing. Apart from strengthening local systems, 
there are wider-scale interventions that could be considered. 
Using a point-of-care VL testing approach for patients with 
clinical failure would result in faster turnaround times by 
circumventing the need for batch testing.3 This could be of  
particular benefit for admitted patients who normally receive 
ART from community clinics a long distance from the 
referral hospital. In the interim, we suggest further evaluation 
of  the possibility of  switching a patient to second-line ART, 
while awaiting VL results, based on the presence of  a clinical 
stage 4 opportunistic infection and a low CD4 count.4,5 This 
would prevent long delays in effective ART for this high-risk 
patient group, who are often suffering from advanced ART 
failure, which exposes them to risk of  further complications 
and death.6
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Figure 3: Patient outcomes at discharge and 8 weeks post-discharge
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